AI Analysis | Feedback

Here are 1-3 brief analogies for OrthoPediatrics:

• The Stryker of pediatric orthopedics.

• Zimmer Biomet, but exclusively for children's orthopedic implants.

AI Analysis | Feedback

• Trauma & Deformity Correction Systems: A comprehensive portfolio of plates, screws, and intramedullary nails designed to treat pediatric fractures, limb deformities, and general orthopedic trauma.
• Spinal Deformity Systems: Specialized instrumentation and implants (e.g., SPINETRACK®) used for surgical correction and fusion of complex spinal deformities like scoliosis in children.
• Growth Modulation Systems: Devices such as PediPlates® that are employed to temporarily or permanently influence bone growth, primarily for correcting angular limb deformities in growing children.
• Mitchell Ponseti® Ankle-Foot Orthosis (AFO) System: A bracing system specifically engineered for the non-surgical treatment and long-term management of clubfoot in infants and young children.

AI Analysis | Feedback

OrthoPediatrics (symbol: KIDS) primarily sells its specialized orthopedic products for children to other companies and healthcare institutions, not directly to individuals. The company's business model is B2B (business-to-business).

Its major customers are hospitals and ambulatory surgical centers where pediatric orthopedic surgeons perform procedures. These institutions purchase OrthoPediatrics' implants, instruments, and other medical devices for use in surgical interventions for children with orthopedic conditions.

Due to the nature of the medical device industry and OrthoPediatrics' diversified sales strategy, no single customer (hospital or healthcare system) accounts for 10% or more of the company's total revenue. As such, OrthoPediatrics does not publicly disclose specific names of individual "major customer companies" as defined by a significant concentration of sales to any one entity. Instead, it serves a broad base of healthcare providers globally.

AI Analysis | Feedback

null

AI Analysis | Feedback

David Bailey, President & CEO

David Bailey was appointed President and CEO of OrthoPediatrics, effective June 1, 2021. He joined the company in 2007, serving in various leadership roles including Domestic and International Sales, Operations, and oversight of the Trauma & Deformity Correction and Scoliosis business units. Bailey was instrumental in building OrthoPediatrics from its early startup days to a publicly traded company. Prior to joining OrthoPediatrics, he worked as a Sales Representative and Independent Distributor for Smith & Nephew Orthopaedics.

Fred Hite, Chief Financial Officer & Chief Operating Officer

Fred Hite joined OrthoPediatrics in February 2015 as Chief Financial Officer and Investor Relations Officer, and assumed the additional role of Chief Operating Officer in 2020. He also serves as a Director on the Board for OrthoPediatrics. Before joining OrthoPediatrics, Mr. Hite spent over ten years as the CFO and Investor Relations Officer of Symmetry Medical, a NYSE-listed public company. During his tenure at Symmetry Medical, the company completed an Initial Public Offering (IPO), a secondary offering, and nine acquisitions. Prior to Symmetry Medical, Mr. Hite spent thirteen years with General Electric in various financial positions.

Daniel Gerritzen, Executive Vice President (Legal) & General Counsel

Daniel Gerritzen serves as the Executive Vice President (Legal) & General Counsel for OrthoPediatrics. Further detailed background information on founding or managing other companies, selling companies, or patterns of managing private equity-backed companies was not readily available in the provided search results.

Gregory Odle, President of Scoliosis

Gregory Odle currently serves as the President of the Scoliosis business unit at OrthoPediatrics, having joined the company in 2007. He has held various leadership positions within OrthoPediatrics throughout his tenure. With 23 years of industry experience, Mr. Odle previously held various sales roles for Smith & Nephew, where he became a District Manager.

Joe Hauser, President of Trauma, Deformity Correction and OPSB

Joe Hauser leads the Trauma and Deformity Correction business at OrthoPediatrics, and also oversees OPSB. He has 13 years of experience in the medical device industry. Mr. Hauser has held various leadership roles with companies such as DJO Global, Biomet (Trauma), and Zimmer (Trauma).

AI Analysis | Feedback

The key risks for OrthoPediatrics (symbol: KIDS) primarily revolve around its financial performance and external health crises.

1. Profitability and Cash Flow Management: OrthoPediatrics is currently in a "high-risk, high-reward scenario" where financial metrics indicate caution. The company has reported a negative return on equity and significant negative free cash flow, as it prioritizes reinvestment in product development and market expansion over immediate profitability. While the company aims to achieve free cash flow positivity by 2026, this remains a critical area requiring close monitoring.
2. Impact of Widespread Health Emergencies: The company's operations and demand for its products are susceptible to risks associated with widespread health emergencies. These include pandemics, epidemics, and infectious disease outbreaks such as COVID-19 and respiratory syncytial virus. Such events can significantly impact product demand and the company's ability to respond to related challenges.

AI Analysis | Feedback

AI Analysis | Feedback

• The total global addressable market is $6.2 billion.
• The U.S. addressable market is $2.8 billion.
• The U.S. specialty bracing market opportunity, expanded through the acquisition of Boston Orthotics & Prosthetics in January 2024, is an additional $500 million.

AI Analysis | Feedback

• Continued Growth in Core Product Segments: The company anticipates ongoing strong performance and expansion in its core Trauma & Deformity and Scoliosis businesses. These segments have consistently demonstrated robust growth, with Scoliosis revenue increasing by 52% and Trauma & Deformity revenue by 31% in Q3 2024 alone. In Q3 2025, Trauma and Deformity business grew by 17% and Scoliosis business growth was 4%. This growth is further bolstered by the OrthoPediatrics Specialty Bracing (OPSB) business.
• Expansion of OrthoPediatrics Specialty Bracing (OPSB) Business: The OPSB segment is a significant growth driver, with robust sales increasing by over 20% in Q3 2025, and the company is actively expanding its clinic footprint. OrthoPediatrics raised its 2025 revenue outlook amid accelerated OPSB clinic expansion.
• Introduction of New Products and Pipeline Development: OrthoPediatrics continually emphasizes its comprehensive product offering and pipeline. Recent product launches, such as VerteGlide and the 3P Hip system, have shown strong early returns and are ahead of expectations, contributing to future revenue. The company currently markets 71 products across key pediatric orthopedic categories.
• Market Share Gains: OrthoPediatrics is actively taking market share across its business, benefiting from its exclusive focus on pediatric orthopedics. Opportunities for increased market share arise as some larger original equipment manufacturers (OEMs) may be pulling products used in pediatric populations, which OrthoPediatrics aims to address with new system introductions.
• International Market Penetration: Global expansion, particularly in regions like Europe and the Middle East, is identified as a key lever for future growth. While there have been some recent challenges in Latin and South America, the company's international revenue still grew by 12% in Q3 2024. International revenue growth was 6% in Q3 2025. OrthoPediatrics distributes its products in the United States and over 71 other countries.

AI Analysis | Feedback

Share Repurchases

• OrthoPediatrics Corp. authorized a stock repurchase program of up to $5,000,000 on August 2, 2024.
• As of September 30, 2025, no shares have been purchased under this program.
• The annual dollar limit on repurchases under the program was reduced to $250,000 after December 31, 2024.

Share Issuance

• In 2025, common shares totaling $1,261,000 were issued to settle an obligation with a vendor.
• Common shares worth $233,000 were issued in connection with the Boston O&P acquisition in 2025.
• Common shares were issued for ApiFix installments totaling $6,929,000 in 2024 and for MedTech installments of $226,000 in 2025 and $133,000 in 2024.

Outbound Investments

• OrthoPediatrics acquired MD Orthopaedics in April 2022 for a transaction valued up to $19.6 million, which included an $8.2 million upfront cash payment, $8.9 million in company stock, and $2.5 million in restricted stock. This acquisition expanded their portfolio to include non-operative clubfoot treatment.
• In January 2024, the company acquired Boston Orthotics & Prosthetics (Boston O&P) for an upfront cash payment of $22 million, establishing its OrthoPediatrics Specialty Bracing (OPSB) division.
• The company made investments in private companies, totaling $2,007,000 in 2025 and $380,000 in 2024.

Capital Expenditures

• Purchases of property and equipment were $10,511,000 in 2025 and $14,525,000 in 2024.
• Annual set deployment, a significant capital allocation for their business model, was guided to be less than $20.0 million for the full year 2024.
• For 2025, the company anticipates approximately $15.0 million in new set deployments, supporting pediatric orthopedic surgeons with comprehensive product offerings.